Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells

Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). In NSCLC patients, an EGFR mutation is likely to be correlated with high levels of expressi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Acta Pharmacol Sin
Main Authors: Jiang, Xiao-Ming, Xu, Yu-Lian, Huang, Mu-Yang, Zhang, Le-Le, Su, Min-Xia, Chen, Xiuping, Lu, Jin-Jian
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group 2017
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5672073/
https://ncbi.nlm.nih.gov/pubmed/28880013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2017.123
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker